UBS Group’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-80,100
| Closed | -$35.2K | – | 11278 |
|
|
2022
Q4 | $35.2K | Buy |
80,100
+75,573
| +1,669% | +$24.5K | ﹤0.01% | 7080 |
|
|
2022
Q3 | $1K | Sell |
4,527
-51,002
| -92% | -$17.5K | ﹤0.01% | 10202 |
|
|
2022
Q2 | $20K | Buy |
+55,529
| New | +$23K | ﹤0.01% | 6910 |
|
|
2022
Q1 | – | Sell |
-20,613
| Closed | -$26K | – | 11310 |
|
|
2021
Q4 | $26K | Buy |
+20,613
| New | +$36.6K | ﹤0.01% | 7566 |
|
|
2021
Q2 | – | Sell |
-41,500
| Closed | -$108K | – | 10063 |
|
|
2021
Q1 | $108K | Buy |
41,500
+32,099
| +341% | +$90.8K | ﹤0.01% | 5908 |
|
|
2020
Q4 | $26K | Buy |
9,401
+5,245
| +126% | +$15.3K | ﹤0.01% | 6765 |
|
|
2020
Q3 | $19K | Buy |
4,156
+2,822
| +212% | +$9.31K | ﹤0.01% | 6368 |
|
|
2020
Q2 | $4K | Buy |
+1,334
| New | +$4.28K | ﹤0.01% | 7496 |
|
|
2020
Q1 | – | Sell |
-4,469
| Closed | -$23K | – | 8580 |
|
|
2019
Q4 | $23K | Sell |
4,469
-32,048
| -88% | -$178K | ﹤0.01% | 6801 |
|
|
2019
Q3 | $236K | Buy |
36,517
+7,373
| +25% | +$50.8K | ﹤0.01% | 5114 |
|
|
2019
Q2 | $182K | Buy |
29,144
+28,434
| +4,005% | +$216K | ﹤0.01% | 4972 |
|
|
2019
Q1 | $8K | Buy |
+710
| New | +$7.07K | ﹤0.01% | 6967 |
|
|
2018
Q4 | – | Sell |
-942
| Closed | -$19K | – | 8416 |
|
|
2018
Q3 | $19K | Buy |
942
+639
| +211% | +$11.6K | ﹤0.01% | 6834 |
|
|
2018
Q2 | $6K | Sell |
303
-3,325
| -92% | -$49K | ﹤0.01% | 7430 |
|
|
2018
Q1 | $39K | Sell |
3,628
-2,399
| -40% | -$38.5K | ﹤0.01% | 5902 |
|
|
2017
Q4 | $254K | Buy |
6,027
+2,617
| +77% | +$117K | ﹤0.01% | 4755 |
|
|
2017
Q3 | $187K | Buy |
3,410
+2,560
| +301% | +$432K | ﹤0.01% | 4885 |
|
|
2017
Q2 | $158K | Buy |
850
+553
| +186% | +$96.9K | ﹤0.01% | 4894 |
|
|
2017
Q1 | $35K | Sell |
297
-539
| -64% | -$56.5K | ﹤0.01% | 5761 |
|
|
2016
Q4 | $83K | Buy |
836
+663
| +383% | +$69.8K | ﹤0.01% | 5426 |
|
|
2016
Q3 | $19K | Sell |
173
-8
| -4% | -$960 | ﹤0.01% | 6346 |
|
|
2016
Q2 | $18K | Hold |
181
| – | – | ﹤0.01% | 6393 |
|
|
2016
Q1 | $17K | Sell |
181
-366
| -67% | -$39K | ﹤0.01% | 6330 |
|
|
2015
Q4 | $79K | Buy |
547
+502
| +1,116% | +$65.3K | ﹤0.01% | 5406 |
|
|
2015
Q3 | $5K | Buy |
+45
| New | +$5.28K | ﹤0.01% | 7746 |
|
Other funds holding SIOX
JC
CIA
BBA
UBS Group's SIOX Position: Q1 2023 in Review
UBS Group sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2023, closing a stake of 80,100 shares — an estimated $35.2K sold.
UBS Group first reported a position in SIOX in Q3 2015 and held it in 25 quarters. The position peaked at $254K in Q4 2017. 4 funds tracked by Wall St. Rank hold SIOX as of Q1 2023.
- UBS Group reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- UBS Group sold 80,100 Sio Gene Therapies Inc. Common Stock shares in Q1 2023, an estimated $35.2K.
- UBS Group first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2015 and held it in 25 quarters.
- UBS Group's Sio Gene Therapies Inc. Common Stock position peaked at $254K in Q4 2017.
- 4 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2023.
Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.